CAJ | 학술논문

目的：探讨以人源RBP-4为靶标的疫苗免疫干预胰岛素抵抗的有效性和可行性，为2型糖尿病治疗新方法的推进提供基础研究数据。方法以T7噬菌体为载体表达人源RBP-4的疫苗经皮下免疫2型糖尿病小鼠，同时设空载体组和空白对照组，经2次免疫后在不同时间点检测体液免疫水平、空腹血糖值及体重，并于20周处死动物进行病理学切片检测。结果 RBP-4疫苗有效诱导了抗RBP-4 IgG抗体的产生，并于12周达到峰值，同时，免疫组的空腹血糖值从第8周开始逐步下降，到第12周时较空载体组和空白组有显著差异，并始终维持在2型糖尿病发病值（7 mmol／L）以下。实验期间，2型糖尿病小鼠未出现蜷缩、竖毛、搔鼻、抽搐等明显异常，免疫组、空载体组小鼠心脏、肝脏、脾脏、肺脏、肾脏组织均未观察到明显病变，表明RBP-4疫苗安全性良好。结论 RBP-4疫苗能显著降低2型糖尿病小鼠的血糖，有可能成为治疗胰岛素抵抗的一个新突破点。
목적：탐토이인원RBP-4위파표적역묘면역간예이도소저항적유효성화가행성，위2형당뇨병치료신방법적추진제공기출연구수거。방법이T7서균체위재체표체인원RBP-4적역묘경피하면역2형당뇨병소서，동시설공재체조화공백대조조，경2차면역후재불동시간점검측체액면역수평、공복혈당치급체중，병우20주처사동물진행병이학절편검측。결과 RBP-4역묘유효유도료항RBP-4 IgG항체적산생，병우12주체도봉치，동시，면역조적공복혈당치종제8주개시축보하강，도제12주시교공재체조화공백조유현저차이，병시종유지재2형당뇨병발병치（7 mmol／L）이하。실험기간，2형당뇨병소서미출현권축、수모、소비、추휵등명현이상，면역조、공재체조소서심장、간장、비장、폐장、신장조직균미관찰도명현병변，표명RBP-4역묘안전성량호。결론 RBP-4역묘능현저강저2형당뇨병소서적혈당，유가능성위치료이도소저항적일개신돌파점。
Objective To explore efficacy of the human RBP-4 vaccine interventions targeting insulin resistance , and provide new ways to treatment of type 2 diabetes .Methods T7 bacteriophage vector expressing human-derived vaccine RBP-4 subcutaneously immunized mice with type 2 diabetes , at the same time set up empty vector group and control group.After the second immunization , detecting humoral immunity levels , fasting plasma glucose value and weight at different time points , and the animals were sacrificed for pathological slice assay at 20 weeks .Results The anti-RBP-4 IgG antibodies induced by RBP-4 vaccine was peaked at 12 weeks , the fasting blood glucose level of immunity group gradual decline from the 8th week to 12 weeks and compared with empty vector group and the control group were significantly different, and always maintain the value (7 mmol/L) or less.During the experiment, mice with type 2 diabetes did not appear straight , vertical hair , scratching nose , convulsions and other obvious abnormalities .The mouse heart, liver, spleen, lung and kidney lesions of Immunization group and vector group have no obviously pathological changes, indicating RBP -4 vaccine safety is good.Conclusion RBP-4 vaccine can significantly reduce fasting blood glucose level in type 2 diabetic mice , it may become a new method in the treatment of insulin resistance .